



Weeneebayko Area Health Authority

·ΔσVd ΔU9^bΓ  
Γ\_οΛΛΠr·Δ ▷PL·Δ·Δσ`

Learn more about WAHA at:  
[www.waha.ca](http://www.waha.ca)

# mRNA COVID-19 VACCINE ELIGIBILITY ALGORITHM FOR VACCINATORS

Revised December 22, 2022.

Meagan Vander Ploeg, Interprofessional Policy & Practice Consultant  
(Weeneebayko Area Health Authority)

Jacquelin Fleming-Hillyer, Practice Consultant Public Health - Immunization File  
(FNIHB-OR, Indigenous Services Canada)

## Important updates about this resource:

Since December 2021, colleagues from Weeneebayko Area Health Authority and Indigenous Services Canada have partnered to produce a 1-page reference, the "mRNA COVID-19 Vaccine Eligibility Algorithm for Vaccinators".

Recently we received a request to "split" the algorithm into two pages: one for Primary Series and a second for Boosters.

Enclosed on **Page 2** of this package you will find an **updated 1-page version** of our complete algorithm including the latest Ontario Ministry of Health Guidance for both primary series and booster mRNA COVID-19 vaccines.

On page 3-4 you will find the **new "split" version**:

Page 3 is mRNA COVID-19 Primary Series vaccines ONLY

Page 4 is mRNA COVID-19 Booster vaccines ONLY

**Please let us know which algorithm you prefer!**

## We want to hear from you!



## Please Vote!


Do you prefer the 1-page complete (primary & booster) algorithm, or the two-page "split" version? **Fill out our survey** by scanning the QR code above or visiting:

<https://forms.office.com/r/4RCF2uMTbw>



# Complete (Primary & Booster) mRNA COVID-19 VACCINE ELIGIBILITY ALGORITHM FOR VACCINATORS

December 22, 2022. Produced by Meagan Vander Ploeg, Interprofessional Policy & Practice Consultant (Weeneebayko Area Health Authority), and Jacquelin Fleming-Hillyer, Practice Consultant Public Health - Immunization File (FNIHB-OR, Indigenous Services Canada)



RECOMMENDED VACCINE AND DOSAGE						
CONSIDER: Primary Series vs. Boosters, Immune Status, & Age:						
PRIMARY SERIES 6 m.o. - 4 y.o. <sup>4</sup> :	PRIMARY SERIES 5-11 y.o.:	PRIMARY SERIES 12-29 y.o.	PRIMARY SERIES ≥30 y.o.	BOOSTERS 5-11 y.o.:	BOOSTERS 12-17 y.o.	BOOSTERS ≥18 y.o.:
Moderna Monovalent 25mcg (0.25mL) <b>or</b> Maroon-Cap Pfizer Monovalent 3mcg (0.2mL) <sup>4,5</sup> <b>Use same product as previous dose(s)</b>	<b>1st dose administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>2nd or 3rd dose: Use same manufacturers as previous dose(s) <u>and</u></b> <b>If 5 y.o. administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>or</b> Moderna Monovalent 25mcg (0.25mL) <sup>6</sup> <b>If 6-11 y.o. administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>or</b> Moderna Monovalent 50mcg <sup>6,7</sup>	Grey-Cap Pfizer Monovalent 30mcg (0.3mL) <sup>6</sup>	Grey-Cap Pfizer Monovalent 30mcg (0.3mL) <b>or</b> Moderna Monovalent 100mcg (0.5mL)	Orange-Cap Bivalent Pfizer 10mcg (0.2mL) <sup>6</sup>	Grey-Cap Pfizer Bivalent 30 mcg (0.3mL) <sup>6</sup>	Moderna Bivalent 50mcg (0.5mL) <sup>8</sup> <b>or</b> Grey-Cap Pfizer Bivalent 30 mcg (0.3mL) <sup>8</sup>

<sup>1</sup>Counsel patients on the benefits of recommended intervals as outlined above. Patients may receive vaccine sooner with informed consent as follows:  
 - 1st or 2nd dose in Primary Series, 6m.o. - 4 y.o.: ≥28 days Moderna, ≥21 days Pfizer;  
 - 1st or 2nd dose in Primary Series, ≥5 y.o. **or** 3rd Dose in 3-Dose for immunocompromised: ≥28 days all mRNA.  
 - 3rd Dose in 3-Dose Maroon-Cap Pfizer Primary Series, 6 m.o. - 4 y.o. : ≥56 days.  
 - Booster Doses, all approved/eligible ages: ≥84 days.

<sup>2</sup>In this tool, "COVID-19 Infection" means date of COVID-19 symptom onset as a household contact of a confirmed case, or date of positive test.

<sup>3</sup>In this tool, "immunocompromised" includes any of the immunocompromised criteria listed in the COVID-19 Vaccine: Canadian Immunization Guide (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>) as referenced in the Ontario Ministry of Health COVID-19 Vaccine Guidance ([https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine\\_COVID-19\\_vaccine\\_admin\\_istration.pdf](https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine_COVID-19_vaccine_admin_istration.pdf)) In these populations, a 3rd dose is considered part of the PRIMARY series.

<sup>4</sup>NACI recommends immunocompromised children aged 6 m.o. - 4 y.o. receive Moderna Monovalent 25 mcg for a 3-dose primary series, if not available, Maroon-cap Pfizer Monovalent 3 mcg can be used for a 4-dose primary series.

<sup>5</sup>6m.o.-4 y.o.: Maroon-Cap Monovalent Pfizer is a 3-dose primary series; requires dilution.

<sup>6</sup>Counsel patients 5-29 y.o. (primary series) and 5-17 y.o. (boosters) that Pfizer is the preferred product for their age demographic unless they are 5-6 y.o. and received Moderna for first dose in their primary series (counsel to continue with the same product). Pfizer Bivalent is also the only bivalent product approved for 5-17 y.o. If after counselling they give informed consent to receive a non-Pfizer product, or for boosters a non-bivalent product, consult clinic team lead prior to administration. Document counselling in COVAX comments. **Exception:** Immunocompromised 6-11 y.o. may receive monovalent Moderna (50mcg)<sup>7</sup> for their 3-dose primary series based on clinical discretion.

<sup>7</sup>Moderna Monovalent comes in various concentrations; both 0.10mg/mL and 0.20mg/mL monovalent products may be used for 50mcg doses (primary series, or boosters if no bivalent available).

<sup>8</sup>Bivalent vaccine is recommended for booster doses for those ≥5 y.o. If bivalent vaccine unavailable and the patient is ≥70 y.o. **and** LTC/RH/CC, Moderna Monovalent 100mcg may be given. Otherwise, if bivalent is not available, use monovalent as appropriate for age/population/dose. **Exception:** Bivalent Moderna (50mcg, 0.5mL) is approved for off-label use in immunocompromised<sup>3</sup> 12-17 y.o. (normally approved ≥18 y.o.) based on clinical discretion with informed consent.


<sup>9</sup>High-Risk populations include those referenced in the Ontario Ministry of Health COVID-19 Vaccine Guidance: [https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine\\_COVID-19\\_vaccine\\_admin\\_istration.pdf](https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine_COVID-19_vaccine_admin_istration.pdf)

**Acronyms:** FNIM: First Nations, Inuit, Metis; HCW: Health Care Worker; LTC/RH/CC: Long Term Care, Retirement Home, Congregate Care; M.o.: months old; Y.o.: years old; ≥: greater than or equal to.



# PRIMARY SERIES mRNA COVID-19 VACCINE ELIGIBILITY ALGORITHM FOR VACCINATORS

December 22, 2022. Produced by Meagan Vander Ploeg, Interprofessional Policy & Practice Consultant (Weeneebayko Area Health Authority), and Jacquelin Fleming-Hillyer, Practice Consultant Public Health - Immunization File (FNIHB-OR, Indigenous Services Canada)



RECOMMENDED VACCINE & DOSAGE	Primary Series Dosing; consider immune status and age:			
	6 months to 4 years of age <sup>4</sup> :	5 to 11 years of age <sup>6</sup> :	12-29 years of age <sup>6</sup> :	≥30 years of age:
	Moderna Monovalent, 25 mcg (0.2mL) <b>or</b> Maroon-Cap Pfizer Monovalent, 3 mcg (0.2mL) <sup>4,5</sup> <b>Use same product as use for any previous dose(s)</b>	<b>1st dose administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>2nd or 3rd dose: Use same manufacturers as previous dose(s) and</b> <b>If 5 y.o. administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>or Moderna Monovalent 25mcg (0.25mL)<sup>6</sup></b> <b>If 6-11 y.o. administer:</b> Orange-Cap Pfizer Monovalent 10mcg (0.2mL) <sup>6</sup> <b>or Moderna Monovalent 50mcg<sup>6,7</sup></b>	Administer Grey-Cap Pfizer Monovalent 30mcg (0.3mL) <sup>6</sup>	Grey-Cap Pfizer Monovalent 30mcg (0.3mL) <b>or</b> Moderna Monovalent 100mcg (0.5mL)

<sup>1</sup>Counsel patients on the benefits of recommended intervals as outlined above. Patients may receive vaccine sooner with informed consent as follows:  
**1st or 2nd dose in Primary Series:**  
 - 6m.o. - 4 y.o.: ≥28 days Moderna, ≥21 days Pfizer;  
 - ≥5 y.o. **or 3rd Dose in 3-Dose for immuno-compromised:** ≥28 days all mRNA.  
**3rd Dose in 3-Dose Maroon-Cap Pfizer Primary Series, 6 m.o. - 4 y.o.:** ≥56 days.

<sup>2</sup>In this tool, "COVID-19 Infection" means date of COVID-19 symptom onset as a household contact of a confirmed case, or date of positive test.  
<sup>3</sup>In this tool, "immunocompromised" includes any of the immunocompromised criteria listed in the COVID-19 Vaccine: Canadian Immunization Guide (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>) as referenced in the Ontario Ministry of Health COVID-19 Vaccine Guidance ([https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine\\_COVID-19\\_vaccine\\_admin\\_istration.pdf](https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine_COVID-19_vaccine_admin_istration.pdf)) In these populations, a 3rd dose is considered part of the PRIMARY series.  
<sup>4</sup>NACI recommends 6 m.o. - 4 y.o. immunocompromised patients receive Moderna Monovalent 25mcg for a 3-dose primary series; if unavailable, Maroon-cap Pfizer Monovalent 3mcg can be used for a 4-dose primary series.

<sup>5</sup>6m.o.-4 y.o.: Maroon-Cap Monovalent Pfizer is a 3-dose primary series; requires dilution.  
<sup>6</sup>5-29 y.o. (primary series) should be counselled that Pfizer is the preferred product for their age demographic **unless** they are 5-6 y.o. and received Moderna as their first dose. If after counselling they give informed consent to receive a non-Pfizer product, consult clinic team lead prior to administration. For 5-6 y.o., counsel to continue with the same product. Document counselling in COVAX comments. **Exception:** Immunocompromised 6-11 y.o. may receive monovalent Moderna (50mcg)<sup>7</sup> for their 3-dose primary series based on clinical discretion.  
<sup>7</sup>Moderna Monovalent comes in various concentrations; both 0.10mg/mL and 0.20mg/mL monovalent products may be used for 50mcg doses (primary series, or boosters if no bivalent available).




# BOOSTER mRNA COVID-19 VACCINE ELIGIBILITY ALGORITHM FOR VACCINATORS

December 21, 2022. Produced by Meagan Vander Ploeg, Interprofessional Policy & Practice Consultant (Weeneebayko Area Health Authority), and Jacquelin Fleming-Hillyer, Practice Consultant Public Health - Immunization File (FNIHB-OR, Indigenous Services Canada)

## Booster Doses

## Footnotes



- Counsel patients on the benefits of recommended intervals** as outlined. Patients may receive a booster vaccine sooner with informed consent after a minimum interval of  $\geq 84$  days.
- High-Risk populations include** those referenced in the Ontario Ministry of Health COVID-19 Vaccine Guidance for high risk populations ([https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19\\_vaccine\\_administration.pdf](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf)).
- In this tool, "COVID-19 Infection" means** date of COVID-19 symptom onset as a household contact of a confirmed case, or date of positive test.
- 5-17 y.o.'s should be counselled** that bivalent Pfizer vaccine is the only bivalent product approved for use in this demographic.
- Bivalent vaccine** is recommended for booster doses for those  $\geq 5$  y.o. If bivalent vaccine unavailable and the patient is  $\geq 70$  y.o. **and** LTC/RH/CC, Moderna Monovalent 100mcg may be given. Otherwise, if bivalent is not available, use monovalent as appropriate for age/population/dose. **Exception:** Bivalent Moderna (50mcg, 0.5mL) is approved for off-label use in immunocompromised<sup>6</sup> 12-17 y.o. (normally approved  $\geq 18$  y.o.) based on clinical discretion with informed consent.
- In this tool, "immunocompromised" includes** any of the immunocompromised criteria listed in the COVID-19 Vaccine: Canadian Immunization Guide (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>) as referenced in the Ontario Ministry of Health COVID-19 Vaccine Guidance ([https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19\\_vaccine\\_administration.pdf](https://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf)).

RECOMMENDED VACCINE & DOSAGE

### CONSIDER: Boosters, Immune Status, & Age:

#### 5-11 years of age:

Orange-Cap Bivalent Pfizer 10mcg (0.2mL)<sup>4,5</sup>

#### 12-17 years of age:

Grey-Cap Pfizer Bivalent 30 mcg (0.3mL)<sup>5</sup>

#### $\geq 18$ years of age:

Moderna Bivalent 50mcg (0.5mL)<sup>5</sup> **or** Grey-Cap Pfizer Bivalent 30 mcg (0.3mL)<sup>5</sup>

### Using our algorithm? Let us know!

Visit:

<https://forms.office.com/r/4RCF2uMTbw>

or scan the QR code with your smartphone. This website includes details on algorithm updates.

Scan the QR code with your mobile device camera to ensure you are using **the most up-to-date version!**



See "Primary Series" or "Complete" mRNA COVID-19 Vaccine Eligibility Algorithm for Vaccinators for primary series dosing